Parvovirus B19 infection as trigger of graft vs. host disease

Behre, Gerhard; Christopeit, Maximilian

doi:10.1111/j.1600-0609.2008.01136.x

Cited by 3 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,57 B19V exanthema can also mimic cutaneous acute GVHD (aGVHD). 12,60 In our study none of the patients with B19V viremia had any specific signs or suspicion of B19V infection. Neither retrospectively did any clinical manifestation (including anemia) correlate significantly with the B19V viremia.…”

Section: Discussionmentioning

confidence: 45%

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Among the immunocompetent, infections with parvovirus B19 (B19V) and human bocavirus (HBoV) 1 range clinically from asymptomatic to severe, while following allogeneic hematopoietic SCT (HSCT) B19V can cause a persistent severe illness. The epidemiology and clinical impact of HBoV1 and the other emerging parvovirus 4 (PARV4) among immunocompromised patients have not been established. To determine the occurrence and clinical spectrum of B19V, PARV4 and HBoV1 infections, we performed a longitudinal molecular surveillance among 53 allogeneic HSCT recipients for pre-and post-HSCT DNAemias of these parvoviruses. Quantitative real-time PCR showed B19V DNA in sera of 16 (30%) patients, at mean levels of 4.6 Â 10 3 , 9.9 Â 10 7 , 1.1 Â 10 10 and 1.6 Â 10 2 B19V DNA copies/mL pre-HSCT (9/53), and at 1 (6/53), 2 (4/53) and 3 months (1/25) post HSCT, respectively. However, no clinical manifestation correlated with the presence of B19V viremia. All B19V sequences were of genotype 1. None of the sera investigated contained PARV4 or HBoV1 DNAs. Our data demonstrate B19V viremia to be frequent among pediatric allogeneic HSCT recipients, yet without apparent clinical correlates. PARV4 or HBoV1 viremias were not seen in these immunocompromised patients.

show abstract

Section: Discussionmentioning

confidence: 45%

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Assessment of graft-versus-host disease is commonly obscured by concomitant diseases, e.g. viral or drug-induced exanthema [2,3], viral hepatitis or viral gastroenteritis. The crucial decision is if, when and to which extent an immunosuppressant should be administered.…”

Section: Introductionmentioning

confidence: 99%

Graft-versus-lymphoma effect in a 64-year-old caucasian woman after allogeneic stem-cell transplantation: a case report

et al. 2009

Self Cite

View full text Add to dashboard Cite

IntroductionThe existence of a graft-versus-lymphoma effect is well established. When lacking a firm diagnosis, however, the clinician is challenged to to weigh the potential benefits of the graft-versus-lymphoma effect against potential dangers of graft-versus-host disease as well as against generalized (viral) infections.Case presentationWe present evidence for a graft-versus-lymphoma effect in a 64-year-old caucasian woman with a transplanted peripheral blood-stem-cell graft from her Human Leukocyte Antigen-identical sister, and propose diagnostic measures to distinguish between graft-versus-host effect, and against viral disease or drug-induced reactions.ConclusionWe were able to identify an allogeneic graft-reaction against progressive lymphoma alongside an erythema consistent with acute graft-versus-host disease of the skin. Establishing a firm diagnosis enabled us to decide against T-cell suppression (such as by using cyclosporine). Anti-lymphoma activity was favoured, by means of the allogeneic graft, local radiation and immunotherapy. This illustrates the importance of a sound differential diagnosis of erythema after allogeneic stem-cell transplantation, including assessment of viral disease of the affected tissue.

show abstract

Parvovirus B19 infection in adult patients after allogeneic stem cell transplantation: our experience of five cases and literature review

Katoh

Ochi

Hiramoto

et al. 2019

Bone Marrow Transplant

View full text Add to dashboard Cite

Parvovirus B19 infection as trigger of graft vs. host disease

Cited by 3 publications

References 2 publications

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Graft-versus-lymphoma effect in a 64-year-old caucasian woman after allogeneic stem-cell transplantation: a case report

Parvovirus B19 infection in adult patients after allogeneic stem cell transplantation: our experience of five cases and literature review

Contact Info

Product

Resources

About